Effect of liposomal bupivacaine for sciatic nerve block on opioid use in patients undergoing maxillofacial reconstruction with free fibular flap: a randomized, controlled trial
Abstract Background We investigated the efficacy and safety of preoperative popliteal sciatic nerve block (PSNB) using liposomal bupivacaine (LB) to reduce perioperative opioid consumption and improve recovery quality in patients undergoing maxillofacial reconstruction with a free fibular flap. Meth...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-06-01
|
| Series: | BMC Anesthesiology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12871-025-03151-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849469917672243200 |
|---|---|
| author | Hai-Yin Wu Xiao-Dong Wang Guo-Li Xiong Xu-Dong Yang Li-Kuan Wang |
| author_facet | Hai-Yin Wu Xiao-Dong Wang Guo-Li Xiong Xu-Dong Yang Li-Kuan Wang |
| author_sort | Hai-Yin Wu |
| collection | DOAJ |
| description | Abstract Background We investigated the efficacy and safety of preoperative popliteal sciatic nerve block (PSNB) using liposomal bupivacaine (LB) to reduce perioperative opioid consumption and improve recovery quality in patients undergoing maxillofacial reconstruction with a free fibular flap. Methods A total of 74 patients were randomly allocated into two groups. The PSNB group received ultrasound guided PSNB using 133 mg of LB after anesthesia induction. In the control group, patients underwent nerve block preparation procedures without puncture or drug injection. The primary endpoint was cumulative opioid consumption during the perioperative period (from anesthesia induction to 48 h post-surgery). The secondary endpoints were the total incidence of moderate to severe pain during the 48 h postoperative period; the incidence of moderate to severe pain during different time periods after surgery; the incidence of PONV within 48 h after surgery; subjective sleep quality within 2 days after surgery; the length of post-surgical hospital stay; all-cause in-hospital mortality; and the incidence of other complications during hospitalization. Results There was no significant difference in cumulative opioid consumption between the control group (3020.0 [2163.0, 3569.5] µg of remifentanil equivalents) and the PSNB group (2856.0 [2204.0, 3771.0] µg; p = 0.863). The incidence of moderate to severe pain at the donor site within 48 h after surgery was significantly lower in the PSNB group (3 [8.1%] of 37 patients) than in the control group (18 [48.6%] of 37 patients; p < 0.001). The consumption of rescue opioids was significantly reduced in the PSNB group (0 [0, 50]) compared with that in the control group (50 [0, 100]; p = 0.007). The subjective sleep quality numeric rating scale score was significantly lower in the PSNB group than in the control group (day of surgery: 6.0 [5.0, 8.0] vs. 8.0 [6.0, 9.0], p = 0.029; postoperative day 1: 5.0 [4.0, 5.0] vs. 7.0 [5.5, 7.5], p < 0.001; postoperative day 2: 5.0 [4.0, 5.5] vs. 6.0 [5.0, 7.5], p = 0.001). The incidence of postoperative nausea and vomiting was significantly lower in the PSNB group (0 [0.0%]) compared with that in the control group (5 [13.5%]; p = 0.021). There was no significant difference in the incidence of adverse events between the two groups. Conclusion Preoperative administration of PSNB by LB did not spare opioids during the intraoperative period, but significantly relieved postoperative pain at the donor site, reduced rescue opioid consumption, and improved postoperative sleep quality, without additional adverse events. Trial registration Clinicaltrials.gov. Identifier ChiCTR2400080944, 19 February 2024. |
| format | Article |
| id | doaj-art-14937380440a416d9cb354538bcb82c6 |
| institution | Kabale University |
| issn | 1471-2253 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Anesthesiology |
| spelling | doaj-art-14937380440a416d9cb354538bcb82c62025-08-20T03:25:19ZengBMCBMC Anesthesiology1471-22532025-06-0125111010.1186/s12871-025-03151-6Effect of liposomal bupivacaine for sciatic nerve block on opioid use in patients undergoing maxillofacial reconstruction with free fibular flap: a randomized, controlled trialHai-Yin Wu0Xiao-Dong Wang1Guo-Li Xiong2Xu-Dong Yang3Li-Kuan Wang4Department of Anesthesiology, Peking University School and Hospital of StomatologyDepartment of Anesthesiology, Peking University School and Hospital of StomatologyDepartment of Anesthesiology, Peking University School and Hospital of StomatologyDepartment of Anesthesiology, Peking University School and Hospital of StomatologyDepartment of Anesthesiology, Peking University School and Hospital of StomatologyAbstract Background We investigated the efficacy and safety of preoperative popliteal sciatic nerve block (PSNB) using liposomal bupivacaine (LB) to reduce perioperative opioid consumption and improve recovery quality in patients undergoing maxillofacial reconstruction with a free fibular flap. Methods A total of 74 patients were randomly allocated into two groups. The PSNB group received ultrasound guided PSNB using 133 mg of LB after anesthesia induction. In the control group, patients underwent nerve block preparation procedures without puncture or drug injection. The primary endpoint was cumulative opioid consumption during the perioperative period (from anesthesia induction to 48 h post-surgery). The secondary endpoints were the total incidence of moderate to severe pain during the 48 h postoperative period; the incidence of moderate to severe pain during different time periods after surgery; the incidence of PONV within 48 h after surgery; subjective sleep quality within 2 days after surgery; the length of post-surgical hospital stay; all-cause in-hospital mortality; and the incidence of other complications during hospitalization. Results There was no significant difference in cumulative opioid consumption between the control group (3020.0 [2163.0, 3569.5] µg of remifentanil equivalents) and the PSNB group (2856.0 [2204.0, 3771.0] µg; p = 0.863). The incidence of moderate to severe pain at the donor site within 48 h after surgery was significantly lower in the PSNB group (3 [8.1%] of 37 patients) than in the control group (18 [48.6%] of 37 patients; p < 0.001). The consumption of rescue opioids was significantly reduced in the PSNB group (0 [0, 50]) compared with that in the control group (50 [0, 100]; p = 0.007). The subjective sleep quality numeric rating scale score was significantly lower in the PSNB group than in the control group (day of surgery: 6.0 [5.0, 8.0] vs. 8.0 [6.0, 9.0], p = 0.029; postoperative day 1: 5.0 [4.0, 5.0] vs. 7.0 [5.5, 7.5], p < 0.001; postoperative day 2: 5.0 [4.0, 5.5] vs. 6.0 [5.0, 7.5], p = 0.001). The incidence of postoperative nausea and vomiting was significantly lower in the PSNB group (0 [0.0%]) compared with that in the control group (5 [13.5%]; p = 0.021). There was no significant difference in the incidence of adverse events between the two groups. Conclusion Preoperative administration of PSNB by LB did not spare opioids during the intraoperative period, but significantly relieved postoperative pain at the donor site, reduced rescue opioid consumption, and improved postoperative sleep quality, without additional adverse events. Trial registration Clinicaltrials.gov. Identifier ChiCTR2400080944, 19 February 2024.https://doi.org/10.1186/s12871-025-03151-6Liposomal bupivacainePopliteal sciatic nerve blockMaxillofacial reconstructionFree fibular flapOpioid sparingPostoperative analgesia |
| spellingShingle | Hai-Yin Wu Xiao-Dong Wang Guo-Li Xiong Xu-Dong Yang Li-Kuan Wang Effect of liposomal bupivacaine for sciatic nerve block on opioid use in patients undergoing maxillofacial reconstruction with free fibular flap: a randomized, controlled trial BMC Anesthesiology Liposomal bupivacaine Popliteal sciatic nerve block Maxillofacial reconstruction Free fibular flap Opioid sparing Postoperative analgesia |
| title | Effect of liposomal bupivacaine for sciatic nerve block on opioid use in patients undergoing maxillofacial reconstruction with free fibular flap: a randomized, controlled trial |
| title_full | Effect of liposomal bupivacaine for sciatic nerve block on opioid use in patients undergoing maxillofacial reconstruction with free fibular flap: a randomized, controlled trial |
| title_fullStr | Effect of liposomal bupivacaine for sciatic nerve block on opioid use in patients undergoing maxillofacial reconstruction with free fibular flap: a randomized, controlled trial |
| title_full_unstemmed | Effect of liposomal bupivacaine for sciatic nerve block on opioid use in patients undergoing maxillofacial reconstruction with free fibular flap: a randomized, controlled trial |
| title_short | Effect of liposomal bupivacaine for sciatic nerve block on opioid use in patients undergoing maxillofacial reconstruction with free fibular flap: a randomized, controlled trial |
| title_sort | effect of liposomal bupivacaine for sciatic nerve block on opioid use in patients undergoing maxillofacial reconstruction with free fibular flap a randomized controlled trial |
| topic | Liposomal bupivacaine Popliteal sciatic nerve block Maxillofacial reconstruction Free fibular flap Opioid sparing Postoperative analgesia |
| url | https://doi.org/10.1186/s12871-025-03151-6 |
| work_keys_str_mv | AT haiyinwu effectofliposomalbupivacaineforsciaticnerveblockonopioiduseinpatientsundergoingmaxillofacialreconstructionwithfreefibularflaparandomizedcontrolledtrial AT xiaodongwang effectofliposomalbupivacaineforsciaticnerveblockonopioiduseinpatientsundergoingmaxillofacialreconstructionwithfreefibularflaparandomizedcontrolledtrial AT guolixiong effectofliposomalbupivacaineforsciaticnerveblockonopioiduseinpatientsundergoingmaxillofacialreconstructionwithfreefibularflaparandomizedcontrolledtrial AT xudongyang effectofliposomalbupivacaineforsciaticnerveblockonopioiduseinpatientsundergoingmaxillofacialreconstructionwithfreefibularflaparandomizedcontrolledtrial AT likuanwang effectofliposomalbupivacaineforsciaticnerveblockonopioiduseinpatientsundergoingmaxillofacialreconstructionwithfreefibularflaparandomizedcontrolledtrial |